FDA Moves Israeli COVID-19 Treatment With 100% Survival Rate Into Clinical Trials
Some hopeful news. One Israeli company has created a treatment for the Wuhan Coronavirus that has thus far proved to be 100 percent effective in treating the virus.
According to the Jerusalem Post, the company Pluristem created a placenta-based cell-therapy that has not only helped patients survive but also improve respiratory parameters to boot. These patients were in dire straights while being tested with organ failures across the board:
The patients were treated at three different Israeli medical centers for one week under the country’s compassionate use program and were suffering from acute respiratory failure and inflammatory complications associated with COVID-19. Four of the patients also demonstrated failure of other organ systems, including cardiovascular and kidney failure.
The Jerusalem Post reported that the company plans to apply to multiple nations to begin clinical trials Full Story - Brandon Morse - RedState
The second coronavirus vaccine trial, with a candidate developed by Inovio Pharmaceuticals, is underway in the US
The second vaccine safety trial for coronavirus is underway in the US using a skin-deep shot instead of the usual deeper jab injected into the muscle.
The pinch should feel like a simple skin test, a researcher told one of the 40 volunteers lying on an exam table in Kansas City, Missouri, on Wednesday.
'It's the most important trial that we've ever done,' Dr John Ervin of the Center for Pharmaceutical Research told The Associated Press afterward.
'People are beating down the door to get into this trial.' Full Story - Daily Mail
China's CanSino Bio advances COVID-19 vaccine into phase 2 on preliminary safety data - CanSino and its collaborators at the Academy of Military Medical Sciences’ Institute of Biotechnology plan to move their adenovirus type-5 vector-based recombinant COVID-19 vaccine, Ad5-nCoV, into phase 2 clinical trial in China “soon,” the company said in a disclosure (PDF) to the Hong Kong Stock Exchange on Thursday.
Why It’ll Still Take More Than a Year to Develop a COVID-19 Vaccine - It’s important to note, though, as more labs announce concepts, plans, and vaccination formulas, that “soon” is a relative term when it comes to vaccines.
My dear old statistics teacher used to say that relying on any model, however good but founded on past data, was like driving by looking at the rearview mirror; fine as long as the future looked like the past. As governments struggle with their response to the COVID-19 pandemic, the $64 trillion question is "which past does the future look like?"